A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

more than 10 bispecific antibodies have been successfully approved by the FDA, and more than 100 are currently in clinical trials, highlighting biopharma’s continued investment within bispecific ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...